Adults 18 to 50, any sex, with Pain. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Visual Analog Scale (VAS) ScorePrimary· Up to 2 hours
Standard computerized scale of perceived pain level. The scale ranges from 0 to 100, a score of "0" indicating "No Pain" and a score of "100" indicating "Most Pain". Higher score indicates a worse outcome as perceived pain is increasing, lower score indicates a better outcome as perceived pain is decreasing.
VAS Score in Response to No Visual Stimulation
Group
Value
95% CI
Healthy Controls
24.77
± 20.51
VAS Score in Response to Flicker Visual Stimulation
Group
Value
95% CI
Healthy Controls
25.02
± 21.55
VAS Score in Response to Abstract Visual Stimulation
Group
Value
95% CI
Healthy Controls
25.19
± 21.13
VAS Score in Response to Semantic Visual Stimulation
Group
Value
95% CI
Healthy Controls
23.64
± 21.19
Event-related Potential (ERP)Primary· Up to 2 hours
Evoked event-related neural response to contact heat perception measured by EEG (electroencephalography), P300 component
Group
Value
95% CI
Healthy Controls
31
Sponsor's own description
The goal of this study is to investigate a novel neuromodulatory approach utilizing visual stimulation to impact pain perception in healthy participants.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dandelion Science
Last refreshed: 7 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06276881.